arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

NEOGEN CORP

NEOG
$13.99 ▲ +0.39 (+2.87%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Bearish
auto_awesome

Analytical Summary

NEOGEN CORP faces fundamental challenges with weakness in Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.0B
Dividend Yield
Revenue Growth -2.7%
Op. Margin -2.5%
ROIC -0.7%
FCF / Share $0.38
Trailing P/E
Price / Book 1.5x
FCF Yield 2.7%
Debt / Equity 0.38
info Valuation on last close. End-of-day price, Sep 22, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$870.40M
↓ -2.7%
Net Income Profit after all expenses
$-7.90M
↑ +99.3%
Operating Margin Operating profit as % of sales
-2.5%
↑ +97.9% 20th
FCF / Share Free cash flow per share
$0.38
↑ +42.6%
Long-Term Debt Long-term obligations
$793.70M
↓ -9.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
34
Returns
38
Financial Health
47
Cash Quality
3

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 66 quarters